May 2023 tender notification
Pharmac is pleased to provide the latest tender results
Download the tender notification [PDF 93 KB]
Tender results
Pharmac has resolved to award tenders for Principal Supply Status for some products included in the 2021/22 Invitation to Tender, dated 1 November 2021 and the 2022/23 Invitation to Tender, dated 31 October 2022.
Some of the pharmaceuticals that will be delisted when the period of Principal Supply Status commences may be subject to existing listing contracts with Pharmac. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. Pharmac will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to Pharmac, the Pharmacy Guild and the NZULM by:
- For new listings, by 4pm on 12 June 2023 or the 5th of the month prior to listing, whichever is earlier
- For price changes, by 4pm on the 12th of the month prior to the date of subsidy change
Pharmac cannot list a product (and pharmacies cannot claim) without this information.
More information about this process and NOPC forms can be found on our website.
Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand(external link) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines(external link).
Pharmacodes and CTPP codes must be provided to Pharmac by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest).
Pharmac cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.
__________________________________________________________________________________
CORRECTION to May 2023 Tender Notification
Change to the footnotes on tables 3 and 5 to read "This product will be supplied at the Price from the 1st 22nd day of the month prior to the listing date, as per Schedule 4 clause 2.3(c)(iii) of the 2022/23 Invitation To Tender."
Correction in table 3 to clarithromycin injection brand name to "Klacid IV".
Corrections in bold and strikethrough below.
2021/22 Tender – Principal Supply Status applies until 30 June 2025
Community Pharmaceutical tenders – Section B of the Pharmaceutical Schedule
The decisions were as follows:
1. Tenders awarded to pharmaceuticals where at least one other brand is listed
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand |
Listing date |
Principal Supply date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|
|
Amoxicillin |
Cap 250 mg; 500 capsule bottle |
$43.45 |
$27.50 |
Miro-Amoxicillin (Miro) |
1 December 2023 |
1 May 2024 |
Alphamox (Viatris) |
|
Amoxicillin |
Cap 500 mg; 500 capsule bottle |
$66.44 |
$41.00 |
Miro-Amoxicillin (Miro) |
1 December 2023 |
1 May 2024 |
Alphamox (Viatris) |
|
Phenobarbitone |
Tab 30 mg; 500 tablet blister pack |
$40.00 |
$398.50 |
Noumed Phenobarbitone |
1 July 2023 |
1 December 2023 |
PSM (API Comsumer brands) |
|
Teriparatide |
Inj 250 mcg per ml, 2.4 ml; 1 device pack |
$490.00 |
$195.00 |
Teriparatide – Teva (Teva) |
1 January 2024 |
1 June 2024 |
Forteo (Eli Lilly) (Pharmacode 2222906) Forteo (Eli Lilly) (Pharmacode 2650908) |
Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule
The decisions were as follows:
2. Tenders awarded to currently listed Pharmaceuticals where at least one other brand is listed
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand |
DV limit |
Listing date |
Principal Supply date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|---|
|
Amoxicillin |
Cap 250 mg; 500 capsule bottle |
$43.45 |
$27.50 |
Miro-Amoxicillin (Miro) |
5% |
1 December 2023 |
1 May 2024 |
Alphamox (Viatris) |
|
Amoxicillin |
Cap 500 mg; 500 capsule bottle |
$66.44 |
$41.00 |
Miro-Amoxicillin (Miro) |
5% |
1 December 2023 |
1 May 2024 |
Alphamox (Viatris) |
|
Phenobarbitone |
Tab 30 mg; 500 tablet bottle |
$40.00 |
$398.50 |
Noumed Phenobarbitone |
5% |
1 July 2023 |
1 December 2023 |
PSM (API Comsumer brands) |
|
Teriparatide |
Inj 250 mcg per ml, 2.4 ml; 1 device pack |
$490.00 |
$195.00 |
Teriparatide – Teva (Teva) |
5% |
1 January 2024 |
1 June 2024 |
Forteo (Eli Lilly) (Pharmacode 2222906) Forteo (Eli Lilly) (Pharmacode 2650908) |
2022/23 Tender – Principal Supply Status applies until 30 June 2026
Community Pharmaceutical tenders – Section B of the Pharmaceutical Schedule
The decisions were as follows:
3. Tenders awarded to currently listed Pharmaceuticals where no other brand is listed
|
Chemical name |
Presentation; |
Current |
New |
Principal Supply brand |
Date of subsidy change |
Principal Supply date |
|---|---|---|---|---|---|---|
|
Fluconazole |
Cap 150 mg; 1 capsule blister pack |
$0.65 |
$0.45 |
Mylan (Viatris) |
1 July 2023 |
1 December 2023 |
|
Fluconazole |
Cap 200 mg; 28 capsule blister pack |
$12.89 |
$8.90 |
Mylan (Viatris) |
1 July 2023 |
1 December 2023 |
|
Imatinib mesilate |
Cap 400 mg; 30 capsule blister pack |
$84.79 |
$69.76 |
Imatinib-Rex (Rex Medical) |
1 July 2023 |
1 December 2023 |
|
Rivaroxaban |
Tab 10 mg; 30 tablet blister pack |
$83.10 |
$15.60 |
Xarelto (Bayer) |
1 July 2023 |
1 December 2023 |
|
Rivaroxaban |
Tab 15 mg; 28 tablet blister pack |
$77.56 |
$14.56 |
Xarelto (Bayer) |
1 July 2023 |
1 December 2023 |
|
Rivaroxaban |
Tab 20 mg; 28 tablet blister pack |
$77.56 |
$14.56 |
Xarelto (Bayer) |
1 July 2023 |
1 December 2023 |
|
Tramadol hydrochloride1 |
Cap 50 mg; 100 capsule blister pack |
$2.80 |
$3.33 |
Arrow-Tramadol (Teva) |
1 August 2023 |
1 January 2024 |
|
Tramadol hydrochloride1 |
Tab sustained-release 100 mg; 20 tablet blister pack |
$1.52 |
$1.95 |
Tramal SR 100 (Seqirus) |
1 December 2023 |
1 May 2024 |
|
Tramadol hydrochloride1 |
Tab sustained-release 150 mg; 20 tablet blister pack |
$2.10 |
$2.95 |
Tramal SR 150 (Seqirus) |
1 December 2023 |
1 May 2024 |
|
Tramadol hydrochloride1 |
Tab sustained-release 200 mg; 20 tablet blister pack |
$2.75 |
$3.80 |
Tramal SR 200 (Seqirus) |
1 December 2023 |
1 May 2024 |
|
1This product will be supplied at the Price from the 1st 22nd day of the month prior to the listing date, as per Schedule 4 clause 2.3(c)(iii) of the 2022/23 Invitation To Tender. |
||||||
4. Tenders awarded to pharmaceuticals where at least one other brand is listed
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand |
Listing date |
Principal Supply date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|
|
Fluconazole |
Tab 50 mg; 28 capsule blister pack |
$2.75 |
$4.10 |
Mylan (Viatris) |
1 July 2023 |
1 December 2023 |
Dizole (Viatris)2 |
|
Imatinib mesilate |
Cap 100 mg; 60 capsule blister pack |
$58.23 (Imatinib-Rex) $2,400.00 (Glivec) |
$44.93 |
Imatinib-Rex (Rex Medical) |
1 July 2023 |
1 December 2023 |
Glivec (Novartis) |
|
Pravastatin |
Tab 20 mg; 100 tablet bottle pack |
$2.11 (per 28 tablets) |
$7.16 |
Pravastatin Clinect (Clinect) |
1 December 2023 |
1 May 2024 |
Pravastatin Mylan (Viatris) Pravastatin Viatris (Viatris) |
|
Pravastatin |
Tab 40 mg; 100 tablet bottle pack |
$3.61 (per 28 tablets) |
$12.25 |
Pravastatin Clinect (Clinect) |
1 December 2023 |
1 May 2024 |
Pravastatin Mylan (Viatris) |
|
2As noted on the Pharmaceutical Schedule, Dizole Cap 50 mg to be delisted on 1 August 2023 |
|||||||
Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule
5. Tenders awarded to Pharmaceuticals where no other brand is listed
|
Chemical name |
Presentation; |
Current |
New |
Principal Supply brand |
DV |
Date of price change |
Principal Supply date |
|---|---|---|---|---|---|---|---|
|
Fluconazole |
Tab 50 mg; 28 capsule blister pack |
$2.75 |
$4.10 |
Mylan (Viatris) |
5% |
1 July 2023 |
1 December 2023 |
|
Fluconazole |
Cap 150 mg; 1 capsule blister pack |
$0.65 |
$0.45 |
Fluconazole |
5% |
1 July 2023 |
1 December 2023 |
|
Fluconazole |
Cap 200 mg; 28 capsule blister pack |
$12.89 |
$8.90 |
Fluconazole |
5% |
1 July 2023 |
1 December 2023 |
|
Imatinib mesilate |
Cap 400 mg; 30 capsule blister pack |
$84.79 |
$69.76 |
Imatinib-Rex (Rex Medical) |
5% |
1 July 2023 |
1 December 2023 |
|
Rivaroxaban |
Tab 10 mg; 30 tablet blister pack |
$83.10 |
$15.60 |
Xarelto (Bayer) |
5% |
1 July 2023 |
1 December 2023 |
|
Rivaroxaban |
Tab 15 mg; 28 tablet blister pack |
$77.56 |
$14.56 |
Xarelto (Bayer) |
5% |
1 July 2023 |
1 December 2023 |
|
Rivaroxaban |
Tab 20 mg; 28 tablet blister pack |
$77.56 |
$14.56 |
Xarelto (Bayer) |
5% |
1 July 2023 |
1 December 2023 |
|
Tramadol hydrochloride3 |
Cap 50 mg; 100 capsule blister pack |
$2.80 |
$3.33 |
Arrow-Tramadol (Teva) |
5% |
1 August 2023 |
1 January 2024 |
|
Tramadol hydrochloride3 |
Inj 50 mg per ml, 1 ml ampoule; 5 |
$4.50 |
$10.00 |
Tramal 50 (Seqirus) |
5% |
1 December 2023 |
1 May 2024 |
|
Tramadol hydrochloride3 |
Inj 50 mg per ml, 2 ml ampoule; 5 |
$3.83 |
$9.00 |
Tramal 100 (Seqirus) |
5% |
1 December 2023 |
1 May 2024 |
|
Tramadol hydrochloride3 |
Tab sustained-release 100 mg; 20 tablet |
$1.52 |
$1.95 |
Tramal SR 100 (Seqirus) |
5% |
1 December 2023 |
1 May 2024 |
|
Tramadol hydrochloride3 |
Tab sustained-release 150 mg; 20 tablet |
$2.10 |
$2.95 |
Tramal SR 150 (Seqirus) |
5% |
1 December 2023 |
1 May 2024 |
|
Tramadol hydrochloride3 |
Tab sustained-release 200 mg; 20 tablet |
$2.75 |
$3.80 |
Tramal SR 200 (Seqirus) |
5% |
1 December 2023 |
1 May 2024 |
|
3This product will be supplied at the Price from the 1st 22nd day of the month prior to the listing date, as per Schedule 4 clause 2.3(c)(iii) of the 2022/23 Invitation To Tender. |
|||||||
6. Tenders awarded to pharmaceuticals where at least one other brand is listed
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand |
DV limit |
Listing date |
Principal Supply date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|---|
|
Alfentanil |
Inj 0.5 mg per ml, 2 ml ampoule; 5 ampoule pack |
$24.75 (per 10 ampoules) |
$8.99 |
Medsurge (Medsurge) |
5% |
1 September 2023 |
1 February 2024 |
Hameln (Max Health) |
|
Clarithromycin |
Inj 500 mg vial; 1 vial pack |
$9.87 |
$9.10 |
Klacid IV (Viatris) |
5% |
1 February 2024 |
1 July 2024 |
Martindale (Max Health) |
|
Dexmedetomidine |
Inj 100 mcg per ml, 2 ml vial; 5 vial pack |
$97.88 |
$42.00 |
Dexmedetomidine Mylan (Viatris) |
5% |
1 December 2023 |
1 May 2024 |
Dexmede-tomidine-Teva |
|
Imatinib mesilate |
Cap 100 mg; 60 capsule blister pack |
$58.23 (Imatinib-Rex) $2,400.00 (Glivec) |
$44.93 |
Imatinib-Rex (Rex Medical) |
5% |
1 July 2023 |
1 December 2023 |
Glivec (Novartis) |
|
Pravastatin |
Tab 20 mg; 100 tablet bottle pack |
$2.11 (per 28 tablets) |
$7.16 |
Pravastatin Clinect (Clinect) |
5% |
1 December 2023 |
1 May 2024 |
Pravastatin Mylan (Viatris) Pravastatin Viatris (Viatris) |
|
Pravastatin |
Tab 40 mg; 100 tablet bottle pack |
$3.61 (per 28 tablets) |
$12.25 |
Pravastatin Clinect (Clinect) |
5% |
1 December 2023 |
1 May 2024 |
Pravastatin Mylan (Viatris) |
Tender declines - Products where no tender is to be awarded for Principal Supply Status
Pharmac has resolved not to award tenders for Principal Supply Status for the following products listed in the 2021/21 Invitation to Tender and 2022/23 Invitation to Tender, dated 1 November 2022 and 31 October 2022 respectively.
|
Chemical name |
Line item |
|---|---|
|
Colistin sulphomethate |
Inj 150 mg |
|
Flecainide acetate |
Inj 10 mg per ml, 15 ml |
|
Glucose [dextrose] |
Solution 15 g |
|
Metaraminol tartrate |
Inj 0.5 mg per ml, 20 ml |
|
Micronazole nitrate |
Vaginal crm 2% with applicator |
|
Morphine |
Tab immediate-release 10 mg |
|
Morphine |
Tab immediate-release 20 mg |
|
Povidone iodine |
Oint 10% |
|
Prednisolone |
Rectal foam 10 – 20% |
|
Teriparatide (widened access) |
Inj 250 mcg per ml |
For products included in the 2020/21, 2021/22 and 2022/2023 Invitation to Tender where no announcement has yet been made, either a decision is still pending subject to Pharmac Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.
If you have any queries regarding this notification, please contact Pharmac on 0800 66 00 50.